Miltefosine (Impavido) for Leishmaniasis

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2014年 / 56卷 / 1451期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [1] Efficacy of miltefosine (Impavido®) for cutaneous leishmaniasis in Colombia
    Soto, Jaime
    Toledo, Julia
    Soto, Paula
    Padilla, Julio
    Sindermann, Herbert
    Anders, Gerlind
    Engel, Jurgen
    Berman, Jonathan
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2005, 73 (06): : 73 - 74
  • [2] Efficacy of miltefosine (Impavido®) for mucocutaneous leishmaniasis in Bolivia
    Soto, Jaime
    Toledo, Julia
    Parra, Rolando
    Balderrama, Margarita
    Rea, Jaime
    Gomez, Ana
    Ardiles, Jaime
    Soto, Paula
    Valda, Luis
    Sindermann, Herbert
    Anders, Gerlind
    Engel, Jurgen
    Berman, Jonathan
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2005, 73 (06): : 346 - 346
  • [3] Miltefosine (Impavido®) in the treatment of mucocutaneous and cutaneous leishmaniasis in Bolivia
    Toledo, Julia
    Soto, Jaime
    Soto, Paula
    Balderama, Margarita
    Rea, Ivan
    Gomez, Ana
    Soto, Jaime
    Parra, Rolando
    Valda, Luis
    Guillen, Ninoshtka
    Anders, Gerlind
    Sindermann, Herbert
    Engel, Jurgen
    Berman, Jonathan
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (05): : 297 - 297
  • [4] Miltefosine (Impavido): the first oral treatment against leishmaniasis
    H. Sindermann
    S. L. Croft
    K. R. Engel
    W. Bommer
    H. J. Eibl
    C. Unger
    J. Engel
    [J]. Medical Microbiology and Immunology, 2004, 193 : 173 - 180
  • [5] Miltefosine (Impavido): the first oral treatment against leishmaniasis
    Sindermann, H
    Croft, SL
    Engel, KR
    Bommer, W
    Eibl, HJ
    Unger, C
    Engel, J
    [J]. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2004, 193 (04) : 173 - 180
  • [6] Impavido® (INN: miltefosine) -: first oral therapy of leishmaniasis
    不详
    [J]. INFECTION, 2005, 33 (03) : 181 - 182
  • [7] Efficacy and tolerability of oral miltefosine (Impavido®) in patients with resistant visceral leishmaniasis
    Engel, KR
    Sindermann, H
    Fischer, C
    Bommer, W
    [J]. Multidisciplinarity for Parasites, Vectors and Parasitic Diseases, Vol 2, 2004, : 57 - 61
  • [8] IMPAVIDO™ (MILTEFOSINE) FOR ANNERGIC DIFFUSE CUTANEOUS LEISHMANIASIS, A RARE AND INTRACTABLE DISEASE
    Hueb, M.
    Oliveira, T. F.
    Grigoli, E.
    Viana, T. R.
    Proenca, W. B.
    Damin, B. C.
    Fonseca-Jr, E. A.
    Carvalho, A. P.
    Cavalcante, L. R. S.
    Reis, P., V
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2019, 113 : S154 - S154
  • [9] Mucosal leishmaniasis and miltefosine
    Tuon, Felipe Francisco
    Amato, Valdir Sabbaga
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (11) : 1525 - 1526
  • [10] Miltefosine to treat leishmaniasis
    Berman, J
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (08) : 1381 - 1388
12345